Last reviewed · How we verify
NCT05253417: CANREST
The CANabidiol Use for RElief of Short Term Insomnia
Phase 2 trial testing 50 mg Cannabidiol (CBD) in Sleep Disturbance in 208 participants. Completed in 7 July 2023.
7 July 2023
Quick facts
| Lead sponsor | Bod Australia |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 208 |
| Start date | 1 May 2022 |
| Primary completion | 7 July 2023 |
| Estimated completion | 7 July 2023 |
| Sites | 2 locations across Australia |
Drugs / interventions tested
- 50 mg Cannabidiol (CBD) — full drug profile →
- Placebo
- 100 mg Cannabidiol (CBD) — full drug profile →
Conditions studied
- Sleep Disturbance — all drugs for Sleep Disturbance →
- Insomnia — all drugs for Insomnia →
- Insomnia Type; Sleep Disorder — all drugs for Insomnia Type; Sleep Disorder →
- Insomnia, Transient — all drugs for Insomnia, Transient →
Sponsor
Bod Australia — full company profile →
Who can join
Adults 18 to 65, any sex, with Sleep Disturbance or Insomnia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol.
Bhuller R, Schlage WK, Hoeng J. · · 2024 · cited 4× · PMID 39394179 · DOI 10.1186/s42238-024-00250-y
Verify or expand the search:
- PubMed search for NCT05253417
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sleep Disturbance
Currently open trials in the same condition.
- NCT07503223 — Sleep Optimization With Acoustic Therapy · NA · recruiting
- NCT07464626 — Virtual vs Physical Art Therapy for Anxiety, Psychological Well-being, and Sleep Quality in Colorectal Cancer Patients · NA · recruiting
- NCT07386691 — Comparing Effect of Intradialytic Aerobic Exercise Versus Incentive Spirometer on Fatigue and Sleep Quality Among Hemodi · NA · active not recruiting
- NCT07354776 — Effect of Isometric Neck Exercises on Cervicogenic Headache, Cortisol, and BDNF in Adolescents With Smartphone Addiction · NA · recruiting
- NCT07119268 — SPARK Healthy Sleep · NA · recruiting
Other Bod Australia trials
Trials by the same sponsor.
- NCT04997395 — Feasibility of Cannabidiol for the Treatment of Long COVID · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05253417 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bod Australia
- Last refreshed: 16 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05253417.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing